MOUNTAIN VIEW, Calif., Feb. 13, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) announced today the completion of its initial public offering of 4,500,000 shares of common stock.  In addition, the underwriters of its initial public offering exercised their over-allotment option in full and purchased an additional 675,000 shares of common stock.  All of such shares were sold by ChemoCentryx at an initial public offering price of $10.00 per share.  J.P. Morgan and Citigroup acted as joint book-running managers of the offering, and Cowen and Company acted as co-manager of the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 8, 2012.  The offering was made only by means of a written prospectus forming a part of the effective registration statement.  Copies of the final prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by phone at 866-803-9204, or from Citigroup, Attn: Prospectus Delivery Department, Brooklyn Army Terminal, 140 58th Street, Brooklyn, New York 11220 or by phone at 718-765-6732.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About ChemoCentryx 

ChemoCentryx, Inc. (NASDAQ: CCXI) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds.

CCXI-G

 

 

 

 

SOURCE ChemoCentryx, Inc.

Back to top

RELATED LINKS
http://www.chemocentryx.com